Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
1930s
|
| gptkbp:atccode |
R01 BA02
|
| gptkbp:brand |
gptkb:Sudafed_PE
Neo-Synephrine Little Noses |
| gptkbp:casnumber |
61-76-7
|
| gptkbp:chemical_formula |
C9 H13 NO2
|
| gptkbp:class |
phenethylamine
|
| gptkbp:clinical_trial |
Phase IV
Phase II Phase III Phase I |
| gptkbp:composed_by |
from benzene
from phenylalanine from phenylacetone from tyrosine |
| gptkbp:contraindication |
gptkb:diabetes
gptkb:ventricular_tachycardia severe hypertension hyperthyroidism |
| gptkbp:dissolved |
soluble in water
soluble in alcohol |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
phenylephrine hydrochloride
|
| gptkbp:interacts_with |
gptkb:digoxin
MAO inhibitors beta-blockers tricyclic antidepressants |
| gptkbp:legal_status |
Over-the-counter
Prescription only |
| gptkbp:lifespan |
2.5 to 3 hours
|
| gptkbp:mechanism_of_action |
alpha-1 adrenergic receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:p_hlevel |
9.2
|
| gptkbp:related_products |
gptkb:pseudoephedrine
ephedrine |
| gptkbp:route_of_administration |
oral
intravenous intranasal |
| gptkbp:side_effect |
headache
nausea hypertension reflex bradycardia |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:used_for |
nasal congestion
hypotension eye dilation |
| gptkbp:bfsParent |
gptkb:Mucinex_Sinus-Max
|
| gptkbp:bfsLayer |
6
|